BR9711753A - Processos de diagnosticar diabete e de triar antagonistas de ipg tipo p ou tipo a, usos de inositolfosfoglicanos (ipgs) tipo p ou tipo a , de antagonistas para ipgs tipo p ou tipo a e de uma mistura de ipgs tipo p e tipo a e composição farmacêutica. - Google Patents

Processos de diagnosticar diabete e de triar antagonistas de ipg tipo p ou tipo a, usos de inositolfosfoglicanos (ipgs) tipo p ou tipo a , de antagonistas para ipgs tipo p ou tipo a e de uma mistura de ipgs tipo p e tipo a e composição farmacêutica.

Info

Publication number
BR9711753A
BR9711753A BR9711753-6A BR9711753A BR9711753A BR 9711753 A BR9711753 A BR 9711753A BR 9711753 A BR9711753 A BR 9711753A BR 9711753 A BR9711753 A BR 9711753A
Authority
BR
Brazil
Prior art keywords
type
ipgs
antagonists
diabetes
inositolfosphoglycans
Prior art date
Application number
BR9711753-6A
Other languages
English (en)
Inventor
Thomas William Rademacher
Patricia Maclean
Original Assignee
Rademacher Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rademacher Group Limited filed Critical Rademacher Group Limited
Publication of BR9711753A publication Critical patent/BR9711753A/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/66—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood sugars, e.g. galactose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

"PROCESSOS DE DIAGNOSTICAR DIABETE E DE TRIAR ANTAGONISTAS DE IPG TIPO P OU TIPO A, USOS DE INOSITOLFOSFOGLICANOS (IPGS) TIPO P OU TIPO A, DE ANTAGONISTAS PARA IPGS TIPO P OU TIPO A E DE UMA MISTURA DE IPGS TIPO P E TIPO A E COMPOSIçãO FARMACêUTICA". é revelado o diagnóstico do diabete, com base no nível ou relação dos inositolfosfoglicanos (IPGs) tipo-P e A, de uma amostra de um paciente, e o uso de IPGs tipo-P e A ou seus antagonistas, no tratamento do diabete. Em particular, a presente invenção fornece o tratamento de IDDM ou diabete tipo II magra (NIDDM), com uma mistura de mediadores tipo-P e A, e o tratamento do diabete tipo II obesa (NIDDM) com um mediador tipo-P e/ou um antagonista tipo -A.
BR9711753-6A 1996-09-11 1997-09-11 Processos de diagnosticar diabete e de triar antagonistas de ipg tipo p ou tipo a, usos de inositolfosfoglicanos (ipgs) tipo p ou tipo a , de antagonistas para ipgs tipo p ou tipo a e de uma mistura de ipgs tipo p e tipo a e composição farmacêutica. BR9711753A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9618934.5A GB9618934D0 (en) 1996-09-11 1996-09-11 Inositol phosphoglycans for therapeutic use in the treatment of diabetes and obesity
PCT/GB1997/002440 WO1998011435A1 (en) 1996-09-11 1997-09-11 Materials and methods relating to the diagnosis and treatment of diabetes and obesity

Publications (1)

Publication Number Publication Date
BR9711753A true BR9711753A (pt) 2000-01-18

Family

ID=10799742

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9711753-6A BR9711753A (pt) 1996-09-11 1997-09-11 Processos de diagnosticar diabete e de triar antagonistas de ipg tipo p ou tipo a, usos de inositolfosfoglicanos (ipgs) tipo p ou tipo a , de antagonistas para ipgs tipo p ou tipo a e de uma mistura de ipgs tipo p e tipo a e composição farmacêutica.

Country Status (12)

Country Link
US (2) US6716592B1 (pt)
EP (1) EP0925503B1 (pt)
JP (1) JP2001505658A (pt)
CN (1) CN1234118A (pt)
AU (1) AU722425B2 (pt)
BR (1) BR9711753A (pt)
CA (1) CA2264829A1 (pt)
DE (1) DE69718018T2 (pt)
ES (1) ES2189970T3 (pt)
GB (1) GB9618934D0 (pt)
IL (1) IL128894A0 (pt)
WO (1) WO1998011435A1 (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9618930D0 (en) * 1996-09-11 1996-10-23 Univ London Metal containing carbohydrates from human tissue which regulate lipogenic activity
GB9801899D0 (en) * 1998-01-29 1998-03-25 Univ London Neurotrophic properties of ipgs analogues
GB9805771D0 (en) * 1998-03-18 1998-05-13 Hoeft Rademacher Limited Materials and methods relating to screening for inositolphosphoglycan mimetics
CA2321113A1 (en) * 1998-03-18 1999-09-23 Thomas William Rademacher Anti-inositolphosphoglycan monoclonal antibodies
US20040192586A1 (en) * 1998-03-18 2004-09-30 Rodaris Pharmaceuticals Limited Materials and methods relating to anti-inositolphosphoglycan antibodies
GB9806645D0 (en) * 1998-03-27 1998-05-27 Univ London Materials and methods relating to the treatment of conditions involving mast cells,basophils and eosinophils
GB9814039D0 (en) * 1998-06-29 1998-08-26 Univ London Materials and methods relating to the prevention or treatment of ischaemia-reperfusion injury
GB9828560D0 (en) * 1998-12-23 1999-02-17 Rademacher Group Limited Substances from porcine tissue
US6953781B2 (en) 2000-05-12 2005-10-11 Rodaris Pharmaceuticals Limited Compounds and their uses
US6939857B2 (en) 2000-05-12 2005-09-06 Rodaris Pharmaceuticals Limited Compounds and their uses
US6759390B2 (en) 2000-05-12 2004-07-06 Manuel Martin-Lomas Compounds and their uses
EP1295122A2 (en) * 2000-05-12 2003-03-26 Rodaris Pharmaceuticals Limited Ipg assay
US6716826B2 (en) 2000-05-12 2004-04-06 Rodaris Pharmaceuticals Limited Compounds and their uses
EP1718327B1 (en) * 2003-06-20 2015-01-07 University of Florida Biomarkers for differentiating between type 1 and type 2 diabetes
US20100168218A1 (en) * 2005-07-26 2010-07-01 Kuhajda Francis P Method of reducing food intake
JP2007063225A (ja) * 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
WO2007061923A2 (en) * 2005-11-18 2007-05-31 Takeda San Diego, Inc. Glucokinase activators
US8034822B2 (en) 2006-03-08 2011-10-11 Takeda San Diego, Inc. Glucokinase activators
EP2049518B1 (en) * 2006-05-31 2011-08-31 Takeda San Diego, Inc. Indazole and isoindole derivatives as glucokinase activating agents.
EP2091947A2 (en) 2006-12-20 2009-08-26 Takeda San Diego, Inc. Glucokinase activators
US8173645B2 (en) * 2007-03-21 2012-05-08 Takeda San Diego, Inc. Glucokinase activators
EP1978408B1 (en) * 2007-03-29 2011-10-12 FUJIFILM Corporation Negative resist composition and pattern forming method using the same
CN102056605A (zh) * 2008-04-04 2011-05-11 罗伯特·绍尔 药物组合物
US8168396B2 (en) 2009-05-11 2012-05-01 Diabetomics, Llc Methods for detecting pre-diabetes and diabetes using differential protein glycosylation

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5668695A (en) * 1979-11-10 1981-06-09 Sankyo Co Ltd Enzyme inhibitor griseolic acid and its preparation
US5750348A (en) 1989-03-08 1998-05-12 The University Of Virginia Patents Foundation Method for detecting insulin resistance
US5183764A (en) 1989-03-08 1993-02-02 University Of Virginia Alumni Patents Foundation Quantitative analysis for diabetic condition predictor involving chiro-inositol
US5427956A (en) 1989-03-08 1995-06-27 The University Of Virginia Patent Foundation Quantitative analysis for diabetic condition predictor
US5122603A (en) * 1989-03-08 1992-06-16 The University Of Virginia Alumni Patents Foundation Purified insulin mediators and purification process for same
YU66892A (sh) 1991-08-20 1995-10-24 Hoechst Ag. Fosfoinositolglikan - peptid sa delovanjem kao insulin
GB9505658D0 (en) * 1995-03-21 1995-05-10 Univ London Hormone and growth factor mimetics

Also Published As

Publication number Publication date
CN1234118A (zh) 1999-11-03
AU4130497A (en) 1998-04-02
US6716592B1 (en) 2004-04-06
IL128894A0 (en) 2000-01-31
AU722425B2 (en) 2000-08-03
CA2264829A1 (en) 1998-03-19
EP0925503B1 (en) 2002-12-18
WO1998011435A1 (en) 1998-03-19
US20040063156A1 (en) 2004-04-01
JP2001505658A (ja) 2001-04-24
EP0925503A1 (en) 1999-06-30
DE69718018T2 (de) 2003-11-06
ES2189970T3 (es) 2003-07-16
GB9618934D0 (en) 1996-10-23
DE69718018D1 (de) 2003-01-30

Similar Documents

Publication Publication Date Title
BR9711753A (pt) Processos de diagnosticar diabete e de triar antagonistas de ipg tipo p ou tipo a, usos de inositolfosfoglicanos (ipgs) tipo p ou tipo a , de antagonistas para ipgs tipo p ou tipo a e de uma mistura de ipgs tipo p e tipo a e composição farmacêutica.
Komori et al. Nitric oxide, ACh, and electrical and mechanical properties of canine arterial smooth muscle
TR199800091T1 (xx) Ba����kl�k hastal�klar�n�n tedavisi i�in terap�tik maddeler olarak kullan�lan ��z�nebilir lenfotoksin-� resept�rleri ve anti-lenfotoksin resept�r� ve ligand� antikorlar�.
KR890700366A (ko) 외과용 재료 및 장치
DE69725293D1 (de) N-(2 oxoacetyl oder sulphonyl)-pyrrolidine/piperidine-2-carbonsäurederivate mit verbesserter multi-drug resistenz aktivität
BRPI0409678A (pt) métodos para identificar um composto, para tratar ou prevenir uma doença ou distúrbio em um humano, para incrementar a função de órgãos, tecidos, ou células excitáveis em um humano e para modular a atividade de um complexo de receptores de citocinas protetor de tecidos em um humano
BR9711752A (pt) Uso de um antagonista de ipg tipo g, composição farmacêutica e processos de diagnóstico de pré-eclâmpsia em uma paciente e de triagem para os antagonistas de ipg do tipo p.
DE3780972T2 (de) Verwendung von spezifischen n-methyl-d-aspartat-rezeptor-antagonisten zur praevention und behandlung von neurodegeneration.
Plummer et al. Assessment of antinociceptive drug effects in the presence of impaired motor performance
WO1997040072A3 (en) Adam proteins and uses thereof
Piper et al. Stress and personality in patients with chronic peptic ulcer
DE68900488D1 (de) Isoxazolderivate zur verwendung als zerebralaktive wirkstoffe und zentralmuskelrelaxantien.
FR2401203A1 (fr) Utilisation de melanges d'aminoalcanols et derives dans la dispersion pigments
Mohammed et al. Central noradrenaline depletion attenuates amphetamine-induced locomotor behavior
CA2175476A1 (en) Opioid receptor: compositions and methods
FI971427A (fi) Peptidit ja niitä sisältävät farmaseuttiset koostumukset
Solders Autonomic function tests in healthy controls and in terminal uraemia
Fischbein et al. Lead poisoning in an art conservator
WO2000025766A3 (en) Use of nk antagonist for treating gastric asthma
Hawkes N-BENZYL-β-CHLOROPROPIONAMIDE (HIBICON®): A New Approach to Anticonvulsant Therapy
Ho et al. Attenuation of the antinociceptive action of the selective κ-opioid receptor agonist, U-50,488 H by ICS-205-930
Pambor et al. Allergic contact dermatitis in children.
Cox et al. Effect of thymectomy on blood T‐cell subsets in myasthenia gravis
Gietzen et al. Effects of calmodulin antagonists on Ca2+-transport ATPase
CA2182486A1 (en) Cyclic neurokinin a antagonists

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: RODARIS PHARMACEUTICALS LIMITED (GB)

Free format text: ALTERADO DE: RADEMACHER GROUP LIMITED

B25G Requested change of headquarter approved

Owner name: RODARIS PHARMACEUTICALS LIMITED (GB)

Free format text: SEDE ALTERADA CONFORME SOLICITADO NA PETICAO NO 016974/RJ DE 04/04/2002.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A , 9A E 10A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1903 DE 26/06/2007.